Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with …

refractory multiple myeloma
tumor cells
bcma
cancer
monoclonal protein
GSK Investigational Site
 (5.0 away) Contact site
  • 8 views
  • 29 Jul, 2021
  • +17 other locations
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

angiotensin
mor202
corticotropin
enzyme inhibitor
immunosuppression
Royal Melbourne Hospital
 (4.2 away) Contact site
  • 23 views
  • 31 Mar, 2021
  • +48 other locations
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, LTT462 and NIS793 in myelofibrosis (MF) subjects.

combinations
polycythemia
ruxolitinib
thrombocytosis
essential thrombocythemia
Novartis Investigative Site
 (6.7 away) Contact site
  • 42 views
  • 08 Jul, 2021
  • +26 other locations
Derazantinib Alone or in Combination With Paclitaxel Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

The purpose of this study is to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel, ramucirumab, or atezolizumab in patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR2 genetic aberrations (GA).

Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 0 views
  • 15 Jul, 2021
  • +69 other locations
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first …

major surgery
pembrolizumab
lenvatinib
carcinoma
systemic therapy
Austin Health ( Site 1600)
 (8.6 away) Contact site
  • 0 views
  • 13 Jul, 2021
  • +21 other locations
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second …

kinase inhibitor
lenvatinib
carcinoma
tyrosine
monoclonal antibodies
Austin Health ( Site 3600)
 (9.0 away) Contact site
  • 0 views
  • 13 Jul, 2021
  • +22 other locations
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Research Site
 (5.4 away) Contact site
  • 0 views
  • 08 Jul, 2021
  • +69 other locations
A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity of MVC-101

Peter MacCallum Cancer Centre, Grattan Street, Parkville, Medical Oncology, Level 2
 (3.2 away) Contact site
  • 0 views
  • 16 May, 2021
  • +4 other locations
A Study of TPX-0131 a Novel Oral ALK Tyrosine Kinase Inhibitor in Patients With ALK+ Advanced or Metastatic NSCLC

A phase 1/2, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC). The study consists of two portions: 1) Phase 1 dose escalation, and 2) Phase 2 efficacy evaluation.

tyrosine
brigatinib
kinase inhibitor
alectinib
lung carcinoma
Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 0 views
  • 28 Jul, 2021
  • +5 other locations
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma. Denosumab has been used for many years to help treat cancers such as prostate cancer and breast cancer, but it is not currently used in melanoma. …

calcium
advanced melanoma
brain metastases
systemic therapy
human chorionic gonadotropin
Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 36 views
  • 04 Apr, 2021
  • +9 other locations